Charles River Laboratories Intl. Inc vs Realty Income Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while Realty Income Corp trades at $54.2 (market cap $51.26B). The key difference: Realty Income Corp is far larger — about 3.6× Charles River Laboratories Intl. Inc's market cap, and Realty Income Corp pays a 6.01% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Realty Income Corp for 127 Days on average.
| CRL | O | |
|---|---|---|
Market Cap | $14.23B | $51.26B |
Volume | 1,176,885 | 12,300,266 |
Sector | Health | Real Estate |
52-Week High | $310.77 | $67.56 |
52-Week Low | $149.93 | $53.35 |
Typical Hold Time | 33 Days | 127 Days |
Enterprise Value | $17.06B | $81.88B |
Dividend Yield | — | 6.01% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
Realty Income (O) trades at $53.35, down 1.66% amid a bearish technical signal, with support at $52. The stock has missed EPS estimates for three consecutive quarters but maintains a 92.56% gross margin and 21.23% net income margin. Recent news highlights its 6% dividend yield and 136 consecutive dividend increases, though rising Treasury yields pressure REIT valuations.
The outlook is mixed: analyst consensus targets $64.80 (21% upside) with a 'Hold' bias, but debt-to-asset ratios have risen to 39.93% (2025). Key risks include interest rate sensitivity and earnings misses, while the dividend track record offers income stability. Investors face trade-offs between yield sustainability and fundamental headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →